What You Ought to Know:
– BillionToOne, a next-generation molecular diagnostics firm with a mission to create highly effective and correct checks which might be accessible to all raises $125M in Collection C funding co-led by Adams Avenue Companions and current investor Hummingbird Ventures with important participation from Baillie Gifford, Neotribe Ventures, Norwest Enterprise Companions, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, amongst others.
– This Collection C funding can be used to develop BillionToOne’s industrial and scientific groups, scale-up lab capability, and conduct scientific research for his or her liquid biopsy take a look at.
Genetic Testing Platform Detects & Measures Illness at Molecular Stage
Co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D., BillionToOne is a molecular diagnostics firm with a mission to make molecular diagnostics extra correct, environment friendly, and accessible for all. The Firm’s QCT molecular counter platform is the one know-how that may rely DNA molecules on the single-count stage with single base-pair precision. BillionToOne’s molecular counting know-how will increase the decision of illness detection utilizing cell-free DNA by over 1000-fold. This know-how is on the core of the Firm’s merchandise. BillionToOne’s flagship product, UNITY Display™, is the one non-invasive prenatal take a look at (NIPT) that may assess fetal threat for frequent recessive situations and aneuploidies from one maternal blood pattern.
In keeping with an unbiased peer-reviewed publication (Choates et al., 2020), lower than half of male companions undergo conventional service screening when indicated, limiting the identification of at-risk pregnancies. UNITY Display™ doesn’t require a paternal pattern to evaluate fetal threat, supporting better fairness in care. The Firm has been rising its market share at an exponential tempo, with take a look at volumes rising greater than 300% 12 months over 12 months within the fiscal 12 months 2021. BillionToOne is making use of this similar molecular counting know-how to a groundbreaking liquid biopsy take a look at that mixes therapy choice with monitoring. This take a look at is slated to launch this 12 months.